Core Viewpoint - Sino Medical reported a significant increase in net profit and revenue for the first half of 2025, despite recent stock price volatility and a notable drop in share price over three consecutive trading days [4][6]. Trading Information Summary - On August 22, 2025, Sino Medical's stock closed at 32.7 yuan, down 4.44%, with a turnover rate of 14.54% and a trading volume of 605,100 shares, amounting to a total transaction value of 2.01 billion yuan [1]. - The capital flow on the same day showed a net outflow of 209 million yuan from main funds, accounting for 10.4% of the total transaction value, while retail investors saw a net inflow of 7.39 million yuan, representing 3.68% of the total [2][7]. Shareholder Changes - As of June 30, 2025, the number of shareholders for Sino Medical was 11,100, an increase of 46 from March 31, 2025, reflecting a growth rate of 0.42% [3][7]. Performance Disclosure Highlights - For the first half of 2025, Sino Medical achieved a main revenue of 240 million yuan, a year-on-year increase of 12.53%, and a net profit attributable to shareholders of 13.84 million yuan, up 296.54% [4][5]. - The second quarter alone saw a main revenue of 140 million yuan, a 13.86% increase year-on-year, and a net profit of 10.87 million yuan, reflecting a 110.56% rise [4]. Company Announcements Summary - Sino Medical's total assets as of the end of the reporting period were approximately 1.31 billion yuan, a 0.70% increase from the previous year, while the net assets attributable to shareholders rose by 3.13% to approximately 894 million yuan [5]. - The company’s R&D expenditure accounted for 32.36% of its revenue, a decrease of 10.80 percentage points compared to the previous year [5].

Core Viewpoint - The stock of Sino Medical Science and Technology Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative decline of 30% over three consecutive trading days from August 20 to August 22, 2025, prompting a regulatory announcement regarding the situation [1][6]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 32.70 yuan per share as of August 22, 2025, with significant volatility exceeding that of most peers and the Shanghai Composite Index [3][10]. - The rolling price-to-earnings (P/E) ratio of the company is reported at 2318.77, significantly deviating from the industry average P/E ratio of 34.84 [3][10]. - The trading turnover rates for August 20, 21, and 22, 2025, were 16.56%, 19.01%, and 14.54%, respectively, indicating a notable increase compared to previous levels [3][10]. Group 2: Company Disclosures and Operations - The company has not identified any significant media reports or market rumors that could impact its stock price, and it confirms that there are no undisclosed major events affecting stock trading [2][8]. - The company’s subsidiary, Sino Shenchang, received FDA breakthrough device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, which signifies recognition of its technological innovation [4][11]. - The breakthrough designation does not guarantee FDA approval for market entry, as further compliance with regulatory requirements is necessary [4][11]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, the company reported net losses of 39.63 million yuan and 1.4978 million yuan, respectively, while the net profit for the first half of 2025 was 13.84 million yuan [5][12].